Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families

Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in homologous recombination (HR) repair of DNA double-strand breaks (DSBs); it also interacts directly with p53. Deleterious mutations have been found in one RAD51 paralog, RAD51C (RAD51L2), in non-BRCA1/2 breast and ovarian cancer families, which suggests that all five paralogs are strong candidate breast cancer susceptibility genes. A genome-wide association study (GWAS) has already identified a single nucleotide polymorphism (SNP) deep within intron 10 of RAD51L1 as a risk locus for breast cancer. Based on its biological functions and association with RAD51C, there is reason to suggest that RAD51L1 (RAD51B/REC2) may also contain high risk mutations in the gene that give rise to multiple-case breast cancer families. In order to investigate this hypothesis, we have used high resolution melt (HRM) analysis to screen RAD51L1 for germline mutations in 188 non-BRCA1/2 multiple-case breast cancer families and 190 controls. We identified a total of seven variants: one synonymous, three intronic, and three previously identified SNPs, but no truncating or nonsense changes. Therefore, our results suggest that RAD51L1 is unlikely to represent a high-penetrance breast cancer susceptibility gene.

[1]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[2]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[3]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[4]  J. Albala,et al.  Identification of a novel human RAD51 homolog, RAD51B. , 1997, Genomics.

[5]  C. Khor,et al.  Strategies for identifying the genetic basis of dyslipidemia: genome-wide association studies vs. the resequencing of extremes , 2010, Current opinion in lipidology.

[6]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[7]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[8]  J. Sambrook,et al.  Dominant negative ATM mutations in breast cancer families. , 2002, Journal of the National Cancer Institute.

[9]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[10]  S. Yokoyama,et al.  Holliday Junction Binding Activity of the Human Rad51B Protein* , 2003, The Journal of Biological Chemistry.

[11]  Eftihia Cayanis,et al.  Association between lipoprotein lipase (LPL) gene and blood lipids: A common variant for a common trait? , 2003, Genetic epidemiology.

[12]  J. Aberle,et al.  Rare variants in the lipoprotein lipase (LPL) gene are common in hypertriglyceridemia but rare in Type III hyperlipidemia. , 2011, Atherosclerosis.

[13]  J. Rommens,et al.  BRCA2 germline mutations in male breast cancer cases and breast cancer families , 1996, Nature Genetics.

[14]  U. Knippschild,et al.  p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. , 1996, The EMBO journal.

[15]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[16]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[17]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[18]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[19]  J. Albala,et al.  The Rad51 Paralog Rad51B Promotes Homologous Recombinational Repair , 2000, Molecular and Cellular Biology.

[20]  F. Bullrich,et al.  Isolation of human and mouse genes based on homology to REC2, a recombinational repair gene from the fungus Ustilago maydis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Garg,et al.  Update on dyslipidemia. , 2007, The Journal of clinical endocrinology and metabolism.

[22]  Franca Fraternali,et al.  Mutation of the RAD51C gene in a Fanconi anemia–like disorder , 2010, Nature Genetics.

[23]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[24]  E. Zeggini,et al.  An Evaluation of Statistical Approaches to Rare Variant Analysis in Genetic Association Studies , 2009, Genetic epidemiology.

[25]  I. Kullo,et al.  Genetic determinants of HDL: monogenic disorders and contributions to variation , 2007, Current opinion in cardiology.

[26]  M. Hayden,et al.  Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. , 2006, Annual review of nutrition.

[27]  Marc Tischkowitz,et al.  RAD51C germline mutations in breast and ovarian cancer patients , 2010, Breast Cancer Research.

[28]  F. Couch,et al.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.

[29]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[30]  Nazneen Rahman,et al.  The emerging landscape of breast cancer susceptibility , 2007, Nature Genetics.

[31]  Zhanwei Wang,et al.  RAD51 135G>C polymorphism contributes to breast cancer susceptibility: a meta-analysis involving 26,444 subjects , 2010, Breast Cancer Research and Treatment.

[32]  C. Harris,et al.  Interaction of p53 with the human Rad51 protein. , 1997, Nucleic acids research.

[33]  J. Burnett,et al.  Common and rare gene variants affecting plasma LDL cholesterol. , 2008, The Clinical biochemist. Reviews.

[34]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[35]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[36]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[37]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[38]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[39]  M. Thun,et al.  Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.

[40]  J. Bai,et al.  RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects , 2010, Breast Cancer Research and Treatment.

[41]  D. Ferguson,et al.  Structure of REC2, a recombinational repair gene of Ustilago maydis, and its function in homologous recombination between plasmid and chromosomal sequences , 1994, Molecular and cellular biology.

[42]  David Wile,et al.  Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. , 2005, Human molecular genetics.

[43]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[44]  L. Fan,et al.  RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies , 2011, Breast Cancer Research and Treatment.

[45]  Robert A. Hegele,et al.  Plasma lipoproteins: genetic influences and clinical implications , 2009, Nature Reviews Genetics.

[46]  M. McCarthy,et al.  Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.

[47]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[48]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[49]  Deborah Hughes,et al.  Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.

[50]  J. Varley.  Germline TP53 mutations and Li‐Fraumeni syndrome , 2003, Human mutation.

[51]  S. Humphries,et al.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk , 2006, Journal of Medical Genetics.

[52]  J. Albala,et al.  Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange. , 2001, Genes & development.

[53]  S. West,et al.  RAD51 localization and activation following DNA damage. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[54]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[55]  J. Nezu,et al.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. , 1998, Nature genetics.

[56]  S. Humphries,et al.  Genetic diagnosis of familial hypercholesterolaemia: a mutation and a rare non-pathogenic amino acid variant in the same family. , 2004, Atherosclerosis.

[57]  K. Miyagawa,et al.  Haploinsufficiency of RAD51B causes centrosome fragmentation and aneuploidy in human cells. , 2006, Cancer research.

[58]  L. Peng,et al.  Analysis of the human RAD51L1 promoter region and its activation by UV light. , 1998, Genomics.

[59]  John L Hopper,et al.  Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource , 2006, Breast Cancer Research.

[60]  M. Rice,et al.  Disruption of muREC2/RAD51L1 in Mice Results in Early Embryonic Lethality Which Can Be Partially Rescued in a p53−/− Background , 1999, Molecular and Cellular Biology.

[61]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[62]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.